Nutex Health (NUTX) Q1 2026 earnings review
Record Net Income Masks Core Margin Compression
Nutex reported a massive 120% YoY jump in Net Income, but investors must look under the hood. The bottom-line surge was almost entirely driven by a $31.5M favorable swing in non-cash stock-based compensation. Operationally, the core business showed signs of strain: Gross Profit dropped 22% and Adjusted EBITDA fell 21% as contract services costs surged. While cash generation remains a bright spot ($75.5M OCF) and the balance sheet is pristine with a record $207.3M in cash, the anemic 0.6% same-store visit growth and rising arbitration costs suggest the IDR-driven hyper-growth phase is decelerating rapidly.
🐂 Bull Case
Operating cash flow accelerated to $75.5M (up from $51.0M a year ago). The company now boasts a record $207.3M in cash against just $41M in total debt, giving them immense flexibility to self-fund their planned 3-5 annual hospital openings.
Nutex continues to dominate the Independent Dispute Resolution (IDR) process, prevailing in over 85% of determinations and collecting over 80% of award amounts, solidifying its revenue base.
🐻 Bear Case
Gross Profit fell by $26.6M YoY despite a slight revenue increase, completely driven by a 56% surge in contract services expenses. Adjusted EBITDA margins collapsed from 34% to 26%.
Same-hospital visits grew a mere 0.6% and same-hospital revenue grew just 0.2%. The hyper-growth phase seen in early 2025 has sharply decelerated to stall speed.
⚖️ Verdict: 🔴
Bearish. Management's narrative focuses on the GAAP Net Income record, but this was fueled by a one-time stock-based compensation credit. The operational reality is a 21% contraction in Adjusted EBITDA, stalling organic volume, and soaring contract expenses.
Key Themes
Soaring Operating Costs Compress Gross Margins
The most alarming data point in the quarter is the collapse in operating leverage. Despite revenue growing 2.2%, total operating costs surged 33.5% ($124.7M vs $93.4M in 25Q1). The primary culprit was 'Contract Services,' which spiked 56.6% to $60.5M. As a result, Gross Profit plummeted from $118.3M to $91.7M. If this cost base is the new normal, the historical margin profile of the business is fundamentally impaired.
Decelerating Organic Traffic
Total hospital visits grew 3.1% YoY to 49,742, but the underlying same-store metric is flashing warning signs. Visits at same hospitals (opened by Dec 2024) increased just 0.6%, and revenue from these hospitals grew 0.2%. This represents a stark deceleration from the 20%+ visit growth the company was printing in early 2025, suggesting market saturation or competitive pressures at mature locations.
Arbitration Costs Creeping Higher
While Nutex maintains an impressive 85% win rate in the IDR process, the cost of fighting these battles is rising. Management disclosed that arbitration costs are now approximating 35% of arbitration-related revenue. This is a material deterioration from Q3 2025, when costs were running at 25%. This diminishing return on IDR claims explains part of the severe margin compression seen this quarter.
Exceptional Liquidity Defends the Balance Sheet
Despite margin concerns, Nutex is an absolute cash-generating machine. The company produced $75.5M in operating cash flow in a single quarter (up 48% YoY). This allowed them to boost their cash pile to $207.3M while paying down long-term debt to just $24.2M. They have removed any near-term financing risk from their growth plans.
Other KPIs
Reversing. Down 20.9% YoY from $72.8 million in 25Q1. This metric strips out the extreme accounting noise of the stock-based compensation swing and exposes the true operational cost pressures facing the business.
Reversing drastically from a $27.6 million expense in 25Q1. This $31.5 million favorable accounting swing is the sole reason GAAP Net Income showed 120% YoY growth. Without it, net income would have declined materially.
Accelerating sequentially. Up 14.2% from $49.7 million just three months ago (Dec 31, 2025). This aligns with the company's note that arbitration costs are consuming a higher percentage of related revenues.
Guidance
Stable. The company reiterated its expectation to open three new hospitals later this year, maintaining its targeted sustainable development pace of three to five hospitals annually.
Key Questions
Contract Services Surge
Contract services expenses jumped 56% YoY despite revenue only growing 2%. What exactly drove this $22 million increase, and should we model this as the new run-rate baseline?
Arbitration Cost Inflation
Arbitration costs are now consuming approximately 35% of arbitration-related revenue, up from roughly 25% mid-last year. What is driving this efficiency degradation, and is there a ceiling to how high this ratio can go?
Stock-Based Compensation Mechanics
Can you unpack the mechanics behind the negative $3.9 million stock-based compensation expense this quarter? Was this a reversal of a previously accrued earn-out that was not met?
Same-Store Stagnation
Same-hospital visits grew just 0.6% YoY. Are we reaching maximum capacity utilization at mature facilities, or are you seeing shifting patient behavior or competitive pressures in those specific markets?